Drug discovery chemistry-driven

As with many areas of drug discovery, mass spectrometry has become intertwined with combinatorial chemistry, especially in the areas of library characterization and screening. Some future advances in mass spectrometry will be driven by the needs of combinatorial chemistry, and mass spectrometry will, to some extent, regulate the progress in combinatorial chemistry. 

This text fills the need for a handbook that is current with respect to the philosophy of analytical chemistry support for drug discovery, development, and post-market support. It is our intention to present the role of analytical research and development as a part of the overall process. For this reason, the chapters are organized in more of a process-driven manner rather than pure function or technique. In all cases, a large number of references are provided for those readers desiring a more in-depth discussion of a particular subject. 

Fig. 15.1-3 Schematic visualization of the various concepts to address chemical and biological space (shaded areas) in drug discovery. Medicinal chemistry focused on compound series (red dots) that had shown activity in pharmacological assays and compound optimization was driven by a tight feedback from biological experiments, leading to a focused nonarrayed addressing of chemical space. The combinatorial promise was to systemically explore the chemical space with diverse arrays of compounds (blue dots) to find the suitable starting points. Analysis of combinatorial chemistry libraries showed their limited...

---